Sun Pharma share price has seen a 10% decline in year-to-date (YTD) performance and an 11% drop over the past six months.

After detailed deliberation, the committee recommended the grant of import and market of Saccharomyces boulardii CNCM-I 745 500 mg powder in Sachet (for oral suspension) with a bioequivalence study ...

Indian pharmaceutical industry welcomes U.S. tariff exemption, boosting stock prices and reinforcing commitment to affordable, quality medicines.

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases ...

China's Bio-Thera Solutions has entered into an exclusive commercialization agreement with India's Dr. Reddy's Laboratories ...

Dr. Reddy’s Laboratories | 43% US sales | Dr ... It would not be surprising if the generic industry is spared as spending on generic & Biosimilar medicines was just ~13% of overall US drug ...

Pharma stocks plummet as Trump threatens tariffs, impacting US-dependent companies and leading to market volatility.

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV Prasad of Dr Reddy's Laboratories. The company is focusing on diversifying ...

Trump hints at unprecedented pharma tariffs, rattling Indian drugmakers. Stocks like Sun Pharma, Cipla, and Dr. Reddy’s plunge as investors fear higher costs, supply disruptions, and pricing pressures ...

Dr. Reddy's Laboratories Ltd. (BSE ... As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an ...

As AI continues to reshape the healthcare industry, Dr. Reddy underscored the need for medical professionals to adapt to this technological shift.